Risk of thrombosis according to need of phlebotomies in patients with polycythemia vera treated with hydroxyurea

Haematologica

Volumn 102, Issue 1, 2017, Pages 103-109

  Alvarez Larrán, Alberto ^a   Pérez Encinas, Manuel ^b   Ferrer Marín, Francisca ^c   Hernández Boluda, Juan Carlos ^d   José Ramírez, María ^e   Martínez López, Joaquín ^f   Magro, Elena ^g   Cruz, Yasmina ^a   Mata, María Isabel ^h   Aragües, Pilar ⁱ   Fox, María Laura ^j   Cuevas, Beatriz ^k   Montesdeoca, Sara ^a   Hernández Rivas, José Angel ^l   García Gutiérrez, Valentín ^m   Gómez Casares, María Teresa ⁿ   Steegmann, Juan Luis ^o   Durán, María Antonia ^p   Gómez, Montse ^d   Kerguelen, Ana ^q   Bárez, Abelardo ^r   García, Mari Carmen ^s   Boqué, Concepción ^t   Raya, José María ^u   Martínez, Clara ^v   Albors, Manuel ^w   García, Francesc ^a   Burgaleta, Carmen ^g   Besses, Carlos ^a   more..

^a HOSPITAL DEL MAR   (Spain)

^b University Hospital of Santiago de Compostela   (Spain)

^c HOSPITAL MORALES MESEGUER   (Spain)

^d HOSPITAL CLÍNICO UNIVERSITARIO   (Spain)

^e HOSPITAL DE JEREZ   (Spain)

^f HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

^g HOSPITAL UNIVERSITARIO PRÍNCIPE DE ASTURIAS   (Spain)

^h Hospital de la Costa del Sol   (Spain)

ⁱ HOSPITAL DE CRUCES   (Spain)

^j Hospitals Universitaris Vall d'H   (Spain)

^k HOSPITAL UNIVERSITARIO DE BURGOS   (Spain)

^l HOSPITAL UNIVERSITARIO INFANTA LEONOR   (Spain)

^m HOSPITAL RAMÓN Y CAJAL   (Spain)

ⁿ HOSPITAL UNIVERSITARIO DE GRAN CANARIA DR NEGRÍN   (Spain)

^o HOSPITAL UNIVERSITARIO DE LA PRINCESA   (Spain)

^p HOSPITAL UNIVERSITARIO SON ESPASES   (Spain)

^q HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

^r Hospital Provincial   (Spain)

^s HOSPITAL GENERAL UNIVERSITARIO DE ALICANTE   (Spain)

^t HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

^u HOSPITAL UNIVERSITARIO DE CANARIAS   (Spain)

^v HOSPITAL DE LA SANTA CREU I SANT PAU   (Spain)

^w Unidad de Enfermedades Infecciosas   (Spain)

more..

Author keywords

[No Author keywords available]

Indexed keywords

HYDROXYUREA;

ADULT; AGED; ARTICLE; BLEEDING; CARDIOVASCULAR RISK; CONTROLLED STUDY; DRUG HYPERSENSITIVITY; FEMALE; HEMATOCRIT; HUMAN; LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; PHLEBOTOMY; POLYCYTHEMIA VERA; THROMBOCYTE COUNT; THROMBOSIS; TREATMENT OUTCOME; TREATMENT RESPONSE; ADOLESCENT; BLOOD CELL COUNT; COMPLICATION; DRUG RESISTANCE; MIDDLE AGED; MULTIMODALITY CANCER THERAPY; MULTIVARIATE ANALYSIS; PHENOTYPE; REGISTER; RISK; SPAIN; TIME FACTOR; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; BLOOD CELL COUNT; COMBINED MODALITY THERAPY; DRUG RESISTANCE; FEMALE; HEMATOCRIT; HUMANS; HYDROXYUREA; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PHENOTYPE; PHLEBOTOMY; POLYCYTHEMIA VERA; REGISTRIES; RISK; SPAIN; THROMBOSIS; TIME FACTORS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 85008420111     PISSN: 03906078     EISSN: 15928721     Source Type: Journal    
DOI: 10.3324/haematol.2016.152769     Document Type: Article

References (14)

1. Gruppo Italiano Studio Policitemia. Polycythemia vera: the natural history of 1213 patients followed for 20 years. Gruppo Italiano Studio Policitemia. Ann Intern Med. 1995;123(9):656-664.
2. Marchioli R, Finazzi G, Landolfi R, et al. Vascular and neoplastic risk in a large cohort of patients with polycythemia vera. J Clin Oncol. 2005;23(10):2224-2232.
3. James C, Ugo V, Le Couedic JP, et al. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature. 2005; 434(7037): 1144-1148.
4. Pearson TC, Wetherley-Mein G. Vascular occlusive episodes and venous hematocrit in primary proliferative polycythaemia. Lancet. 1978;2(8102):1219-1222.
5. Landolfi R, Di Gennaro L, Barbui T, et al. Leukocytosis as a major thrombotic risk factor in patients with polycythemia vera. Blood. 2007;109(6):2446-2452.
6. Cervantes F, Arellano-Rodrigo E, Alvarez-Larrán A. Blood cell activation in myeloproliferative neoplasms. Haematologica. 2009; 94(11):1484-1488.
7. Barbui T, Barosi G, Birgegard G, et al. Philadelphia-negative classical myeloproliferative neoplasms: critical concepts and management recommendations from European LeukemiaNet. J Clin Oncol. 2011;29(6):761-770.
8. Marchioli R, Finazzi G, Specchia G, et al. Cardiovascular events and intensity of treatment in polycythemia vera. N Engl J Med. 2013;368(1):22-33.
9. Tefferi A, Thiele J, Orazi A, et al. Proposals and rationale for revision of the World Health Organization diagnostic criteria for polycythemia vera, essential thrombocythemia, and primary myelofibrosis: recommendations from an ad hoc international expert panel. Blood. 2007;110(4):1092-1097.
10. Barosi G, Birgegard G, Finazzi G, et al. A unified definition of clinical resistance and intolerance to hydroxycarbamide in polycythaemia vera and primary myelofibrosis: results of a European LeukemiaNet (ELN) consensus process. Br J Haematol. 2010; 148(6):961-963.
11. Spivak JL. Polycythemia vera: myths, mechanisms, and management. Blood. 2002;100(13):4272-4290.
12. Alvarez-Larrán A, Pereira A, Cervantes F, et al. Assessment and prognostic value of the European LeukemiaNet criteria for clinicohematologic response, resistance, and intolerance to hydroxyurea in polycythemia vera. Blood. 2012;119(6):1363-1369.
13. Alvarez-Larrán A, Kerguelen A, Hernández-Boluda JC, et al. Frequency and prognostic value of resistance/intolerance to hydroxyurea in 890 patients with polycythemia vera. Br J Haematol. 2016;172 (5):786-793.
14. McMullin MF, Wilkins BS, Harrison CN. Management of polycythaemia vera: a critical review of current data. Br J Haematol. 2016;172(3):337-349.